This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search
Button

Menu

Close

HomeBRAF-mutant mCRC and MOABRAF-mutant mCRC and MOA

Example of description text sitting alongside header

Unmet need in BRAF-mutant mCRCPeer perspectives in BRAF-mutant mCRCMOALabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEfficacy​​​​​Efficacy

Example of description text sitting alongside header

Trial designSelect patient characteristicsOverall survivalOverall response rate/Duration of responseProgression-free survivalLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkSafetySafety

Example of description text sitting alongside header

Adverse reactionsLab abnormalitiesLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkDosingDosing

Example of description text sitting alongside header

Dosing & administrationDose reductionsLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkResourcesResources

Example of description text sitting alongside header

Access & patient supportMaterialsOncologist resourcesVideosLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Prescribing InformationMedication GuideIndicationPatient Site
Access & patient supportMaking your patients’ support needs a priority. Together.

At Pfizer Oncology Together, patient support is at the core of everything we do. We've gathered resources and developed tools to help patients and their loved ones throughout BRAFTOVI treatment. From helping to identify financial assistance options to connecting patients to resources for emotional support, our patients' needs are our priority.

Personalized Patient Support

When your patients and their caregivers need support for their day-to-day challenges with treatment, we want to be a place they can turn to for help. At Pfizer Oncology Together, our Care Champions, who have social work experience, can connect patients prescribed BRAFTOVI to resources that may help with some of their daily needs.*

Access & Reimbursement Assistance

Pfizer Oncology Together is committed to supporting patients as they navigate access to prescribed Pfizer Oncology medications. We offer tools and resources to help patients receive their prescribed BRAFTOVI in a timely manner, including benefits verification and information related to prior authorizations, appeals, product distribution, and billing and coding. 

Emotional Support

We can connect patients to diagnosis-specific support groups, an independent organization that offers short-term counseling, and a free app, developed by Pfizer Oncology, to help patients connect with loved ones and ask for the support they need.

Educational Support

To help support patients’ mental well-being and physical health, we’ve created resources on topics like nutrition, stress management, and communication.

Practical Support

If patients need assistance with transportation or lodging for treatment-related appointments, we'll connect them to independent organizations that offer these services for free to qualifying patients.

ReferencesSome services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.BRAFTOVI is available through specific specialty pharmacies

To help your patients access the medication you’ve prescribed, we can provide a list of specialty pharmacies.

Visit PfizerOncologyTogether.com to see the complete list of specialty pharmacies in the BRAFTOVI distribution network.

 Visit the website LoadingPatient Financial Assistance

Pfizer Oncology Together can help patients understand their insurance benefits and connect them with financial assistance resources (if needed), regardless of their insurance coverage.

Commercially Insured

Resources for eligible patients with commercial, private, employer, or state health insurance marketplace coverage:

  • Co-pay assistance: Eligible, commercially insured patients may pay as little as $0 per month for BRAFTOVI. Limits, terms, and conditions apply.† Patients may receive up to $25,000 per product in savings annually. There are no income requirements, forms, or faxing to enroll
ReferencesPatients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $25,000 per product in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For any questions, please call 1-877-744-5675, visit PfizerOncologyTogether.com/terms or write: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560. Medicare/Government Insured

Help identifying resources for patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans who express a financial need and may be eligible:

  • We can assist patients with searching for financial support from alternate funding resources, which may include financial assistance through Extra Help, a Medicare Part D Low-Income Subsidy (LIS) program
  • If support from alternate funding resources or Medicare Extra Help is not available, Pfizer Oncology Together will see if your patient is eligible for the Pfizer Patient Assistance Program,‡ which can provide prescribed Pfizer Oncology medications for free
 Uninsured

Help identifying resources for patients without any form of healthcare coverage who may be eligible:

  • We can check patient eligibility for Medicaid and help them understand how to apply
  • Patients who do not qualify for Medicaid may receive free medication through the Pfizer Patient Assistance Program‡ or at a savings through the Pfizer Savings Program.§ Patients must be eligible and reapply as needed§
ReferencesThe Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.The Pfizer Savings Program is not health insurance. For more information, call the toll-free number 1-877-744-5675. There are no membership fees to participate in this program. Estimated savings are 50% and depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased.A free app designed to help manage life with cancer

LivingWith® is a free app, designed to help patients connect with loved ones, ask for the support they need, remember important information from doctors’ visits, and stay organized, all in one place.

Download LivingWith for free.

Available in English and Spanish.

 

 Learn more LoadingReferencesDisclaimer: The LivingWith® app is available to anyone living with cancer and their loved ones and is not specific to BRAFTOVI.Resources Patient Brochure Download Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2023 Pfizer Inc. All rights reserved.

PP-BRA-USA-0329
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 


PP-BRA-USA-0232
INDICATION AND USAGE

BRAFTOVI® (encorafenib) is indicated, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
 

Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF CRC.​​​​​​​

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS


New Primary Malignancies, cutaneous and non-cutaneous, can occur with BRAFTOVI. In the BEACON CRC trial, cutaneous squamous cell carcinoma (cuSCC), including keratoacanthoma (KA), occurred in 1.4% of patients with CRC, and a new primary melanoma occurred in 1.4% of patients who received BRAFTOVI in combination with cetuximab. Perform dermatologic evaluations prior to initiating treatment, every 2 months during treatment, and for up to 6 months following discontinuation of treatment. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Dose modification is not recommended for new primary cutaneous malignancies. Based on its mechanism of action, BRAFTOVI may promote malignancies associated with activation of RAS through mutation or other mechanisms. Monitor patients receiving BRAFTOVI for signs and symptoms of non-cutaneous malignancies. Discontinue BRAFTOVI for RAS mutation-positive non-cutaneous malignancies.

Tumor Promotion in BRAF Wild-Type Tumors: In vitro experiments have demonstrated paradoxical activation of MAP-kinase signaling and increased cell proliferation in BRAF wild-type cells exposed to BRAF inhibitors. Confirm evidence of BRAF V600E or V600K mutation using an FDA-approved test prior to initiating BRAFTOVI. 

Hemorrhage: In BEACON CRC, hemorrhage occurred in 19% of patients receiving BRAFTOVI in combination with cetuximab; Grade 3 or higher hemorrhage occurred in 1.9% of patients, including fatal gastrointestinal hemorrhage in 0.5% of patients. The most frequent hemorrhagic events were epistaxis (6.9%), hematochezia (2.3%), and rectal hemorrhage (2.3%). Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.

Uveitis: Uveitis, including iritis and iridocyclitis, has been reported in patients treated with BRAFTOVI. Assess for visual symptoms at each visit. Perform an ophthalmological evaluation at regular intervals and for new or worsening visual disturbances, and to follow new or persistent ophthalmologic findings. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.

QT Prolongation: BRAFTOVI is associated with dose-dependent QTc interval prolongation in some patients. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during BRAFTOVI administration. Withhold, reduce dose, or permanently discontinue for QTc >500 ms.

Embryo-Fetal Toxicity: BRAFTOVI can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with BRAFTOVI and for 2 weeks after the final dose. Advise females to contact their healthcare provider of a known or suspected pregnancy.

Lactation: Advise women not to breastfeed during treatment with BRAFTOVI and for 2 weeks after the final dose.

Infertility: Advise males of reproductive potential that BRAFTOVI may impair fertility.

Risks Associated with Combination Treatment: BRAFTOVI is indicated for use as part of a regimen in combination with cetuximab. Refer to the prescribing information for cetuximab for additional risk information.

ADVERSE REACTIONS

The most common adverse reactions (≥25%, all grades) in the BRAFTOVI with cetuximab arm compared to irinotecan with cetuximab or FOLFIRI with cetuximab (control) were: fatigue (51% vs 50%), nausea (34% vs 41%), diarrhea (33% vs 48%), dermatitis acneiform (32% vs 43%), abdominal pain (30% vs 32%), decreased appetite (27% vs 27%), arthralgia (27% vs 3%), and rash (26% vs 26%). Other clinically important adverse reactions occurring in <10% of patients who received BRAFTOVI in combination with cetuximab was pancreatitis.

The most common laboratory abnormalities (≥20%, all grades) in the BRAFTOVI with cetuximab arm compared to irinotecan with cetuximab or FOLFIRI with cetuximab (control) were: anemia (34% vs 48%) and lymphopenia (24% vs 35%).

DRUG INTERACTIONS

Avoid coadministration of BRAFTOVI with strong or moderate CYP3A4 inhibitors (including grapefruit juice) or CYP3A4 inducers and use caution with sensitive CYP3A4 substrates. Avoid coadministration of BRAFTOVI with hormonal contraceptives.

Modify BRAFTOVI dose if coadministration with a strong or moderate CYP3A4 inhibitor cannot be avoided.

Avoid coadministration of BRAFTOVI with drugs known to prolong QT/QTc interval.

Dose reductions of drugs that are substrates of OATP1B1, OATP1B3, or BCRP may be required when used concomitantly with BRAFTOVI.

Refer to the cetuximab prescribing information for recommended dosing and safety information.

Please see full Prescribing Information including Medication Guide for BRAFTOVI.

INDICATION AND USAGE BRAFTOVI® (encorafenib) is indicated, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF CRC.​​​​​